Merck Research Laboratories, North Wales, Pennsylvania 19454, USA.
Clin Cancer Res. 2010 Feb 15;16(4):1085-7. doi: 10.1158/1078-0432.CCR-09-3246. Epub 2010 Feb 9.
Unlike other diseases, dose-selection for cancer therapeutics is often based on the maximum-tolerated dose in phase 1 studies involving relatively few patients. In this issue of Clinical Cancer Research, Jain and colleagues provide evidence that lower doses may be as effective as maximum-tolerated doses in the treatment of cancer patients.
与其他疾病不同，癌症治疗的剂量选择通常基于涉及相对较少患者的 1 期研究中的最大耐受剂量。在本期《临床癌症研究》中，Jain 及其同事提供了证据，表明较低的剂量可能与最大耐受剂量一样有效治疗癌症患者。
